SpectraCure at G&W Capital Market Day, 2018

SpectraCures CEO Masoud Khayyami will present the company, including the status of the ongoing clinical study, at G&W Capital Market Day on February 23th, at 10:00 AM.

Location: Berns Salonger, Kammarsalen, Berzelii Park, Stockholm

The presentation can also be followed via webcast at https://tv.streamfabriken.com/2018-02-23-spectracure

For further information, contact:
SpectraCure AB publ, CEO, Masoud Khayyami, phone: +46(0) 70 815 21 90

SpectraCure in short

SpectraCure was founded in 2003 as a spin off from Lund University departments for medical laser applications and physics. The company focuses on cancer treatments using medical systems with laser light sources and reactive drugs, which is referred to as "Interstitial Photodynamic Therapy", PDT, a treatment methodology suitable for internal solid tumours of various kind, e.g. prostate and abdominal salivary glands, but also other indications such as cancer of the head and neck.

Release

SpectraCure is developing the future systems for the treatment of internal solid cancer tumours. The goal of the proprietary and patented treatment system is to eliminate deep-seated cancer tumours and prolong the survival of cancer patients while maintaining their quality of life. When prostate cancer recurs, there are often no established treatment options other than lifelong hormone therapy, with its associated side effects. 

Facebook Linkedin Envelope